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Abstract This systematic review focuses on the literature evidence for residual ovarian function during treatment with hormonal
contraceptives. We reviewed all papers which assessed residual ovarian activity during hormonal contraceptive use, using endo-
crine markers such as serum anti-Müllerian hormone (AMH) concentrations, FSH, LH, oestradiol, progesterone and sonographic markers
such as antral follicle count (AFC), ovarian volume and vascular indices. We considered every type (oestroprogestin or only proges-
tin) and dosage of hormonal contraceptive and every mode of administration (oral, vaginal ring, implant, transdermal patch). We
performed an electronic database search for papers published from 1 January 1990 until 30 November 2015 using PubMed and MEDLINE.
We pre-selected 113 studies and judged 48 studies suitable for the review. Most studies showed that follicular development contin-
ues during treatment with hormonal contraceptives, and that during treatment there is a reduction in serum concentrations of FSH,
LH and oestradiol, and also a reduction in endometrial thickness, ovarian volume and the number and size of antral follicles. The
ovarian reserve parameters, namely AFC and ovarian volume, are lower among users than among non-users of hormonal contracep-
tion; regarding the effect of hormonal contraception on AMH, there are still controversies in the literature.
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Introduction
The most important effect of hormonal contraception is the
inhibition of hypothalamo-pituitary axis causing a decrease
in FSH and LH, leading to the suppression of follicular activ-
ity and ovulation. In the last 50 years, the composition of hor-
monal contraceptives has undergone several modifications in
order to reduce as much as possible the side effects, and to
increase the compliance of women, while preserving contra-
ceptive efficacy. Scientific literature shows that reducing the
dose of oestrogen of combined contraceptives, to minimize
its adverse effects, is associated with a decrease in pitu-
itary gonadotrophin secretion, particularly during the hormone-
free interval (HFI) or following missed doses, resulting in
greater follicular development (Baerwald and Pierson, 2004).
In this regard, several studies have evaluated the residual
ovarian function during treatment with hormonal contracep-
tives, comparing different doses of steroids, duration of the
HFI, and administration schemes. Many authors tried to study
the ovarian function using endocrine markers like serum anti-
Müllerian hormone (AMH) concentrations, FSH, LH, oestra-
diol, progesterone and sonographic markers such as antral
follicle count (AFC), ovarian volume and vascular indices. The
aim of this review is to give a complete evaluation of re-
sidual ovarian activity during hormonal contraceptive use.
Materials and methods
The present systematic review included all scientific ar-
ticles which assessed residual ovarian activity during hor-
monal contraceptive use. All articles reporting ovarian activity
as evaluated with either sonographic parameters or biochemi-
cal parameters were included. Studies were excluded if re-
porting only biochemical parameters. Every type and dosage
(oestroprogestin [EP] or only progestin) of hormonal contra-
ceptive and every mode of administration (oral, vaginal ring,
implant, transdermal patch) were considered.
Included studies were randomized clinical trials, prospec-
tive controlled studies, prospective cohort studies or retro-
spective studies with a sample ≥30 patients in good health.
Studies about women in breastfeeding or overweight were ex-
cluded. Only articles written in English were included.
An electronic database search was performed using PubMed
and MEDLINE for the identification of articles published from
1 January 1990 to 30 November 2015, using the combination
of the following search terms: contraceptives, hormonal con-
traceptives, contraception, hormonal contraception, steroid
contraception, oral contraception, oestroprogestins, fol-
licle, follicle development, follicular development, hormone-
free interval, ovarian activity, ovarian function, AMH, LH, FSH,
follicle cysts, ovarian cysts, ovulation, ultrasound. Three in-
vestigators independently conducted this search. After the
search, all relevant studies were retrieved based on the title
and the abstract content, and their reference lists were
checked manually to identify additional potential studies. The
full text of the identified papers was analysed indepen-
dently by three investigators with the purpose of determin-
ing whether or not to include the article in the systematic
review. In cases of incomplete data, studies were excluded.
In cases of disagreement in the review process, consensus was
achieved through the involvement of other investigators.
One hundred and thirteen studies were pre-selected after
the electronic search based on the article title and ab-
stract, and after a manual search of the reference lists of the
full articles. After reading of the full text, a total of 67 ar-
ticles were excluded. A total of 46 studies were therefore
judged suitable for the review (Figure 1).
Ovarian function during combined
contraceptive use
It has been shown that oestrogens and progestins at the con-
centrations above physiological level, produce a negative feed-
back effect on the hypothalamo-pituitary axis (Wan et al.,
1981). Presumably reduced gonadotrophin-releasing hormone
(GnRH), FSH and LH concentrations inhibit ovarian follicular
growth and consequently suppress ovulation and concep-
tion. The progestins have been shown to prevent the LH surge
and ovulation (Barnhart et al., 1997; Tafurt et al., 1980). The
oestrogens are believed to suppress the development of pre-
antral and medium-sized antral follicles in primates (Koering
et al., 1991, 1994), presumably through suppression of FSH
secretion. Moreover, oestrogens have the function of improv-
ing satisfaction of patients avoiding irregular bleeding pat-
terns. However, during the use of EP, residual follicular activity
has been shown to persist. In women using a combined oral
contraceptive (COC), the degree of follicular activity seems
to depend on the dose of ethinyl oestradiol (EE) rather than
on the dose and type of progestin. (Fauser and Van Heusden,
1997; Spellacy et al., 1980). In fact, during low EE dose for-
mulations use, greater numbers and bigger diameter of fol-
licles are observed (Teichmann et al., 1995). Therefore, the
decrease of oestrogen dose in COC could reduce the degree
of hypothalamo-pituitary ovarian suppression especially after
missed doses, or during HFI. Indeed, in women using COC, fol-
licular growth appears to take place more frequently during
HFI, where there is a loss of endocrine suppression (Rabe et al.,
1997).
Three prospective studies examined ovarian function in
women using a single formulation of COC (Deb et al., 2012;
Hoogland and Skouby, 1993; Spona et al., 2010). A prospec-
tive cohort study compared ovarian reserve markers between
users and non-users of hormonal contraception (Bentzen et al.,
2012).
In a prospective study Deb et al. (2012) analysed
sonographic and endocrine markers in 34 women who had been
using a COC containing 30 μg EE + 150 μg levonorgestrel (LNG)
with HFI for a period longer than one year, compared with
36 controls who had not used a COC within the previous year.
The COC group had a significantly lower number of antral fol-
licles measuring ≥6 mm (P < 0.001) and significantly lower
ovarian volume, (P < 0.001); the vascular indices were also
lower in the COC group than in controls but the number of
small antral follicles measuring 2–6 mmwas similar among the
two groups. As regards endocrine markers, FSH, LH and oes-
tradiol concentrations were significantly lower in the COC
group (P < 0.05), but serum AMH concentrations were not sta-
tistically different between the two groups.
In another prospective study the authors evaluated oes-
tradiol values and performed ultrasound scans in 87 women
that used 30 μg EE + 75 μg gestodene (GSD) for two cycles.
They monitored the ovarian activity by describing follicle-
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like structures (FLS) at ultrasound scans and measured oes-
tradiol and P-values creating a score (Table 1). Oestradiol
values were <0.1 nmol/l in women where no FLS were re-
trieved. The authors concluded that ultrasound analysis offers
an adequate evaluation of residual ovarian activity and its
degree could be considered a parameter of COC efficacy
(Hoogland and Skouby, 1993).
In 2010, Spona et al. studied 40 women that used a COC
containing 20 μg EE + 2 μg chlormadinone acetate for three
cycles given in a 24/4-day regimen. FLS size, hormone con-
centrations (oestradiol, progesterone), cervical reaction and
endometrial thickness were analysed. The degree of ovarian
activity was assessed with the Hoogland and Skouby (H/S) score
(Table 1). The authors did not find ovarian activity in 75% of
medication cycles, but they observed residual ovarian activ-
ity in 15.9% and development of a luteinized unruptured fol-
licle in 1.1% of COC cycles. Endometrial thickness was reduced
in medication cycles to 4–5 mm compared with 10–12 mm
without steroid contraception. Finally, in medication cycles,
oestradiol and progesterone were lower than without medi-
cation (Spona et al., 2010).
Some authors quantified the effect of hormonal contra-
ception on both endocrine and sonographic ovarian reserve
markers in 228 women using hormonal contraception and 504
non-users. Among users, 217 (95.2%) received COC and 11
(4.8%) received a contraceptive vaginal ring. Among the users
of COC, 101(46.5%) took monophasic preparations with 20 μg
EE, 96 (44.2%) took monophasic preparations with 30–35 μg
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Figure 1 Flow diagram showing the selection of articles for inclusion in the review.
Table 1 Scoring system used to assess ovarian activity (adapted from Hoogland and Skouby, 1993).
Score
Activity Size of FLS (mm) Oestradiol in
serum (nmol/l)
Progesterone in
serum (nmol/l)
1 No activity ≤10 – –
2 Potential activity >10 – –
3 Non-active FLS >13 ≤0.1 –
4 Active FLS >13 >0.1 ≤5
5 LUF >13, persisting >0.1 >5
6 Ovulation >13, ruptured >0.1 >5
FLS = follicle-like structure; LUF = luteinized unruptured follicle.
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EE and 20 (9.2%) used biphasic/triphasic COC. On day 2–5 of
the menstrual cycle or during withdrawal bleeding, blood sam-
pling and transvaginal sonography was performed. After ad-
justing for age, ovarian reserve parameters were lower among
users than among non-users of hormonal contraception, in par-
ticular serum AMH concentration by 29.8%, AFC by 30.4% and
ovarian volume by 42.2%. AFC in all follicle diameter catego-
ries (small, 2–4 mm; intermediate, 5–7 mm; large, 8–10 mm)
was lower in users than in non-users of hormonal contracep-
tion. A negative linear association was identified between the
duration of hormonal-contraception use and ovarian reserve
parameters. There was not a dose–response relationship
between the dose of EE and AMH or AFC. This study indi-
cates that ovarian reserve markers are reduced in women
taking hormonal contraception. Therefore, it is believed that
in these women AMH concentration and AFC may not be ac-
curate indicators of ovarian reserve (Bentzen et al., 2012).
Ovarian function and steroid dose and
administration schemes
When COC were first introduced during the 1960s, a regimen
based on 21 days of hormone treatment, followed by a 7-day
HFI was created to mimic women’s natural monthly men-
strual cycles in order to achieve greater compliance and ac-
ceptability; hence it was not necessarily based on scientific
evidence. Nevertheless, many authors indicate that the re-
duction of HFI or hormonal supplementation during HFI are
beneficial in COC users as they result in a greater suppres-
sion of ovarian function (Kroll et al., 2015; Schlaff et al., 2004;
Vandever et al., 2008).
Different COC formulation
There are two prospective (Crosignani et al., 1996; Jokubkiene
et al., 2012) and seven randomized studies (Baerwald et al.,
2004; Fitzgerald et al., 1994; Grimes et al., 1994; Rossmanith
et al., 1997; Van der Does et al., 1995; Van Heusden and
Fauser, 1999; Young et al., 1992) evaluating the ovarian func-
tion in women using different COC formulations.
Jokubkiene et al. estimated with three-dimensional (3D)
ultrasound the ovarian volume, the number and volume of
antral follicles, and with power Doppler, vascular indices such
as vascularization index (VI), flow index (FI) and vasculariza-
tion flow index (VFI), in women taking COC. Two hundred and
ten women were included, in particular 151 were on mono-
phasic COC and 59 on triphasic COC. One hundred and ten
women were using COC with classic progestins (LNG and
norethisterone [NET]) and 100 were using progestins
(desogestrel [DSG], GSD, norgestimate [NGM], drospirenone
and cyproterone acetate [CPA]); the oestrogen dose used was
20 μg or 30–35 μg EE. The authors detected significant varia-
tions between the different types of COC, as regards ovarian
volume, number of antral follicles, size of the largest fol-
licle, total follicular volume and vascular indices. Younger
women (20–29 years old) had a significantly higher number
of antral follicles measuring from 2.0–10.0 mm bilaterally, the
right ovary was larger and contained more antral follicles than
the left one compared with older women (30–39 years old).
In all women with follicles ≤10 mm, the sonographic markers
ranged without a clear difference among groups as follows:
ovarian volume from 1–16 cm3, the total follicular volume from
0.03–2.7 cm3, VI from 0.0–13.4%, FI from 0–38, and VFI from
0.0–4.7. There was no significant variation in the proportion
of women with follicle(s) >10.0 mm between the different COC
formulations. The authors also showed that 11% of subjects
using COC for three or more cycles had follicles >10 mm in
at least one ovary on cycle day 4–8. These conclusions show
that there is a great variability in sonographic markers (2D,
3D or Doppler) in women using COC and offer new informa-
tion of normal findings in the ovaries of these women
(Jokubkiene et al., 2012).
A randomized study assessed the ovarian follicular devel-
opment in 36 women receiving one of these three COC regimes
as follows: 35 μg EE for days 1–21 with 180 μg NGM for days
1–7, 215 μg NGM for days 8–14 and 250 μg NGM for days 15–
21; 30 μg EE + 150 μg DSG for 21 days; 20 μg EE + 100 μg LNG
for 21 days for 3 consecutive cycles of 21 days of hormonal
treatment followed by 7 days of HFI. The follicular develop-
ment was evaluated by ultrasound scan every third day. Fol-
licles >10 mmwere found in 16 of 36 women (44%) and follicles
>14 mm were found in 9 of the 17 women (53%) who showed
higher EE concentrations (mean maximum concentration of
630.6 ± 112.5 pmol/ml). Eighty-six percent of follicles >10 mm
grew during HFI. No ovulations were documented. These
results suggest that follicular growth to a diameter compa-
rable to that of ovulatory follicles in natural cycles is ob-
served during compliant COC use and is associated with initial
recovery of endocrine activity that usually can occur during
the HFI (Baerwald et al., 2004).
Another study evaluated the pituitary-ovarian recovery that
emerged during HFI in women using three different low-
dose COC. Hormone concentrations (LH, FSH, oestradiol) were
determined and daily ultrasound scans were performed to es-
timate follicle number and size in 44 healthy women using
one of the following three regimes: 20 μg EE + 75 μg GSD, 20 μg
EE + 150 μg DSG or 30 μg EE + 150 μg DSG. No ovulations were
observed. At the beginning of HFI, hormones concentrations
were not statistically significantly different between the study
groups. FSH concentrations were significantly greater at the
end of the HFI in the 30 μg EE group compared with both 20 μg
EE groups (P = 0.001). Follicular size was significantly smaller
at the beginning and at the end of HFI in the 30 μg EE group
compared with both 20 μg EE study groups. Dominant fol-
licles (diameter >10 mm) were retrieved at the end of HFI only
in the 20 μg EE study groups (in 27% of women taking 20 μg
EE + 75 μg GSD and 18% of women taking 20 μg EE + 150 μg
DSG, respectively). Finally, the area-under-the-curve for oes-
tradiol was statistically significantly lower in the 30 μg EE group
compared with both 20 μg EE groups. These results prove that
the degree of residual ovarian activity at the beginning of HFI
is determined by EE dose rather than the progestin compo-
nent of COC (Van Heusden and Fauser, 1999).
Rossmanith et al. enrolled 118 women to evaluate the in-
hibition of ovarian activity and anticonceptive action on the
cervix and endometrium during use of two low-dose mono-
phasic COC for three treatment cycles: 20 μg EE, 500 μg NET
(group a); 20 μg EE, 150 μg DSG (group b). Hormone concen-
trations (LH, FSH, oestradiol and progesterone) were mea-
sured and simultaneous ultrasound evaluations (to determine
follicular development, cysts and endometrial thickness) were
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performed to examine ovarian activity. No ovarian activity
was observed in most of the treatment cycles (90.8% of group
a and 97.2% of group b, respectively). Follicular activity or
cyst development were found only in a few of the investi-
gated cycles (10.4% of group a and 2.8% of group b, respec-
tively). Gonadotrophin concentrations were suppressed in most
treatment cycles (group a: 76.6% versus group b: 84.8%). Fol-
licular activity was detected in 19.3% (group a) versus 12.2%
(group b) of all cycles, in association with oestradiol serum
concentrations >0.1 nmol/l. No ovulations were observed,
combining ultrasound parameters and hormone concentra-
tions, in any treatment cycle, however, in 4.1% (group a) versus
2.9% (group b) of investigated cycles, serum progesterone con-
centrations exceeded 5 nmol/l, indicating that ovulation had
presumably occurred. Endometrial thickness and cervical
mucus quantity and quality were suppressed during most pill
cycles. In conclusion ovarian activity seems to be inhibited
in the majority of cycles in women using low-dose contra-
ceptives (Rossmanith et al., 1997).
Others authors enrolled 51 women taking COC, to evalu-
ate ovarian activity by means of ultrasound monitoring of fol-
licular growth and serum hormone concentrations (oestradiol
and progesterone). Twenty-two women used a triphasic COC
containing 35 μg EE + 50 μg DSG in the first seven tablets; 30 μg
EE + 100 μg DSG in tablets 8–14, and 30 μg EE + 150 μg DSG
in tablets 15–22; 29 women took one of the two COC con-
taining 20 μg EE; 20 μg EE + 150 μg DSG (15 women) or 20 μg
EE + 75 μg GSD (14 women). Women received COC for 86 treat-
ment cycles. Follicular growth was detected in nine pa-
tients with similar frequency during the 3rd or 4th cycle (9%)
and during the 6th, 7th or 8th cycle (11%). Hormone concen-
trations were suppressed in any cycle but there was no cor-
relation between FLS and oestradiol and progesterone serum
concentrations. These observations suggest that, even with
low-dose COC use, residual ovarian activity could persist
without ovulation (Crosignani et al., 1996).
In a randomized trial of 1995, Van Der Does et al. evalu-
ated the presence of ovulation, assessed combining by trans-
vaginal ultrasound evaluation and serum oestradiol, and
progesterone determinations in 31 women using two tripha-
sic COC: the first containing 30 μg EE + 50 μg LNG (days 1–6),
40 μg EE + 75 μg LNG (days 7–11) and 30 μg EE + 125 μg LNG
(days 12–21), the second containing 35 μg EE + 50 μg DSG (days
1–7), 30 μg EE + 100 μg DSG (days 8–14) and 30 μg EE + 150 μg
DSG (days 15–21), during six cycles of hormonal therapy. No
evidence of ovarian activity was reported in 10 subjects. The
remaining 21 women grew follicles during HFI but FLS were
reduced in volume or disappeared in the first pill week. One
woman using triphasic DSG showed a luteinized unruptured
follicle and in one woman receiving triphasic LNG ovulation
presumably had occurred. The two triphasic COC inhibited
ovarian activity at the same level. Ovarian activity tended to
increase with prolonged COC use in both treatment groups
(Van der Does et al., 1995).
Grimes et al. estimated the risk of follicular develop-
ment and ovulation in 40 women randomized to three dif-
ferent pill regimens (a triphasic pill containing 0.5 μg NET +
35 μg EE on days 1–7, 0.75 μg + 35 μg on days 8–14 and 1 μg
+ 35 μg on days 15–21, followed by 7 days of inert tablets; a
monophasic pill containing 1.0 μg NET + 35 μg EE for 21 days
followed by 7 days of inert tablets; and a monophasic pill con-
taining 0.5 μg NET + 35 μg EE for 21 days followed by 7 days
of inert tablets) or to non-steroidal contraception. Vaginal ul-
trasonography was performed to evaluate follicular devel-
opment and serum progesterone concentrations were
measured to establish if ovulation occurred. Women using the
higher-dose monophasic pill had an increased likelihood to
develop a FLS >30 mm during a treatment cycle (relative risk
[RR] 0.5). Women taking a monophasic or multiphasic pill had
a comparable risk to grow FLS (RR 1.3). With the multipha-
sic pill the maximum ovulation rate over 60 cycles was 1.7
per 100 cycles. In conclusion, the lower-dose rather than the
higher-dose monophasic pill showed the same effectiveness
of the multiphasic pill in its suppression of follicular devel-
opment (Grimes et al., 1994).
Young et al. compared the incidence, risk, size and time
to resolution of ovarian follicles, evaluated with ultrasound
scans in healthy women who took lower-dose and triphasic
COC or a placebo. Forty-eight patients were randomized to
use a monophasic pill with 30 μg EE + 1.5 μg NET acetate taken
for 21 days or a triphasic pill containing the same progestin
dosage with 20, 3, and 35 μg EE taken on days 1–5, 6–12 and
13–21, respectively. Sixty-three percent of placebo-treated
subjects developed follicles >18 mm, compared with 39% and
23% in the triphasic and monophasic pill groups. The risk for
each group of developing a large follicle during a single cycle
was not different. No dominant follicle persisted for >2 weeks
for any subject. In conclusion, the follicular development con-
tinues during treatment with COC. In addition, the findings
fail to support the hypothesis that triphasic COC result in per-
sistent ovarian cysts (Young et al., 1992).
Other authors compared in a randomized study the influ-
ence of two low-dose monophasic COC on the suppression of
ovulation by means of hormonal concentrations (oestradiol
and progesterone) determination and transvaginal ultra-
sound evaluation. They enrolled 52 women receiving one of
two low-dose monophasic COC (20 μg EE + 75 μg GSD or 20 μg
EE + 150 μg DSG) for three treatment cycles. No ovulations
were observed in any COC group. Some FLS in association with
serum oestradiol concentration increase were described in 21%
of women in at least one treatment cycle. The two com-
bined COC showed no significant differences on the residual
ovarian function. Hormone concentrations were signifi-
cantly decreased throughout all three treatment cycles. Mean
LH and FSH concentrations were similar with both prepara-
tions. (Fitzgerald et al., 1994).
COC versus vaginal ring
In a randomized open-label trial, Duijkers et al. compared the
action of the combined contraceptive vaginal ring and a COC
on ovarian function. Forty women were randomly allocated
to receive the vaginal ring (NuvaRing, 21 subjects) or a COC
(30 μg EE + 150 μg LNG, 19 subjects) for two months. The
vaginal ring was initiated on cycle day 5, COC on cycle day
1. Ultrasound parameters (follicular size and endometrial
thickness) and hormone serum concentrations (FSH, LH, oes-
tradiol and progesterone) were analysed. The median
maximum follicular diameter (maxFD) was ≤11 mm during hor-
monal therapy. Women using the vaginal ring showed more
follicles than women taking a COC, in the first treatment cycle,
because of the different onset of preparations. MaxFD were
not different in the second treatment cycle. In both groups,
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oestradiol and progesterone concentrations remained low
during hormonal therapy. No ovulations were described. Both
preparations showed a similar effect on the suppression of
ovarian activity. In the first treatment cycle, for the differ-
ent onset of the two contraceptives, ovarian activity was lower
in the COC group. In the second cycle, ovarian inhibition was
comparable between the two study groups (Duijkers et al.,
2004).
Transdermal patch
In an open-label study in 2004, Heger-Mahn et al. enrolled 199
healthy women, aged between 18 and 35 years, to deter-
mine the effectiveness in the inhibition of ovulation of a trans-
dermal, combined hormonal contraceptive patch containing
0.9 mg EE+ 1.9 mg GSD. Women used one patch per week for
3 weeks, followed by 1 week of no treatment, for two months.
The H/S score was used to determine ovarian activity by means
of transvaginal ultrasonography and serum hormone mea-
surements (oestradiol, progesterone and LH). No ovulation was
observed in all participants. A return to ovulation was ob-
served in 85.7% of women during the first month after the
ending of hormonal therapy (Heger-Mahn et al., 2004).
Modification of the HFI
Three randomized studies (Killick et al., 1998; Rible et al.,
2009; Spona et al., 1996) and one prospective study (Sullivan
et al., 1999) evaluated the suppression of ovarian activity after
HFI modifications.
In 1996, Spona et al. performed a double-blind study of
60 multicentre randomized women, based on the adminis-
tration of 20 μg EE +75 μg GSD for 21 or 23 days to assess the
suppressive action on ovarian activity. Diameters of FLS were
calculated by ultrasound scans. By means of ultrasound study
(to evaluate follicular growth) and determination of LH, FSH,
oestradiol and progesterone serum concentrations, they
noticed a suppression of ovarian activity most pronounced in
the 23-day scheme. Thus, they came to the conclusion that
shortening the HFI in the low-dose COC regime may in-
crease the margin of safety in women. Indeed, the 23-days
formulation adequately suppresses the ovulation, allows a good
cycle control and does not increase the incidence of side
effects (Spona et al., 1996).
In 1998, a prospective, randomized, double-blind trial in-
cluded 47 women to assess the effect of low EE doses, given
during the nominal HFI, on the ovarian activity. They admin-
istered 20 μg EE + 150 μg DSG for 21 days followed by either
a placebo for 7 days or a placebo for 2 days and 10 μg EE for
5 days. During each treatment cycle, ultrasound scans and
hormone concentration determinations (oestradiol and pro-
gesterone) were performed to evaluate ovarian activity.
Women taking 10 μg EE per day during the last 5 days of the
7-day nominal HFI showed a bigger inhibition of ovarian ac-
tivity and reduced folliculogenesis than provided by the
placebo in women using the same 150 μg DSG +20 μg EE
regimen during the first 21 days of each cycle. It is shown that
the administration of EE during the HFI, more effectively sup-
presses ovarian follicular activity (Killick et al., 1998).
In 1999, a prospective cohort study enrolled 58 women,
who were given 15 μg EE + 60 μg GSD for 21 or 24 days, to
compare the ovulation suppression and the ovarian func-
tion. Ultrasonographic data and serum hormone concentra-
tions (oestradiol, progesterone, FSH and LH) were determined
to measure ovarian activity. Ovulation occurred when a FLS
of 13 mm in size was detected and its rupture occurred within
48 h in association with serum oestradiol and progesterone
concentrations of 0.03 ng/ml and 1.6 ng/ml, respectively, in
the same cycle. They observed that women taking a COC with
15 μg EE + 60 μg GSD in a 24-day regimen, showed greater
ovarian suppression with reduced determination of FLS and
lower serum oestradiol concentrations (Sullivan et al., 1999).
In 2009, other authors evaluated 41 women in an open-
label trial, with the aim of documenting the differences in
follicular growth during a 7-day versus 4-day HFI in a COC
scheme with 20 μg EE + 1 mg NET acetate for three 28-day
pill cycles. Ovarian activity was evaluated by means of
hormone concentration assays (FSH, LH, oestradiol, proges-
terone and inhibin B concentrations) and ultrasound scan
evaluating ovarian follicular growth and endometrial thick-
ness. Follicle size of the largest visible FLS was measured and
a H/S score was calculated. It was shown that administering
a COC with 20 μg EE + 1 mg NET acetate for 21 days with 7-day
HFI or for 24 days with 4-day HFI, there was no significant dif-
ference in follicular growth and ovarian steroid activity in two
different regimens. This result indicates that the benefits of
a shortened HFI may be altered by the progestin formula-
tion used (Rible et al., 2009).
Continuous versus cyclical contraception
Ovarian function during continuous versus cyclical contra-
ception was evaluated by one prospective study (Archer et al.,
2009) and two randomized studies (Birtch et al., 2006; Legro
et al., 2008).
In 2006, Birtch et al. enrolled 36 women in a randomized
study to evaluate the ovarian follicular growth during cyclic
versus continuous COC dosing regimens, in order to deter-
mine the follicular growth during the HFI and following COC
discontinuation. Each woman received one of two different
monophasic COC formulations (30 μg EE + 150 μg LNG or 35 μg
EE + 250 μg NGM) for three 28-day cycles according to either
a conventional (21 days) or continuous regimen. Transvagi-
nal ultrasonography was executed to examine ovarian
follicular development. Progesterone and oestradiol concen-
trations were measured. They showed that for both formu-
lations more dominant follicles developed during conventional
oral contraceptive than continuous oral contraceptive use
(8 versus 0, respectively; P = 0.01). The continuous regimen
resulted, therefore, more effective in preventing ovulation
(Birtch et al., 2006).
A prospective randomized double-blind trial of 62 pa-
tients determined the effect of continuous versus cyclical oral
contraception on the ovarian function. Women were given
20 μg EE + 1 mg NET acetate for 6 cycles of 28 days each, in
the form of continuous regimen or with a pause of 7 days. Ul-
trasound scans for ovarian size and endometrial thickness were
performed and serum concentrations of sex steroids, gonado-
trophins, insulin, glucose, lipid profile, sex hormone-binding
globulin (SHBG) and urinary concentrations of estrone
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3-glucuronide (E1G) and pregnanediol 3-glucuronide (PdG)
were assayed. Women in the continuous group showed a sig-
nificant reduction of serum oestradiol and integrated urinary
oestrogens from baseline and had smaller ovaries and domi-
nant follicles, demonstrating that the continuous regimen is
associated with greater suppression of ovarian function (Legro
et al., 2008).
Another prospective study enrolled 37 patients using a con-
tinuous COC, namely oral 90 μg LNG + 20 μg EE, to evaluate
the suppression of ovulation and time to return to ovulation
after interrupting hormonal therapy. Ultrasound scans and
serum hormone measurements (oestradiol, progesterone, FSH
and LH) were performed to characterize ovarian activity. The
continuous LNG + EE regimen (28 days for 3 cycles) com-
pletely suppressed ovulation, with poor follicular growth docu-
mented by ultrasound and with fast recovery of ovulation after
interrupting COC use (Archer et al., 2009).
Supplementation of the HFI with EE
Three randomized studies (Schlaff et al., 2004; Seidman et al.,
2015; Vandever et al., 2008) and one prospective study (Kroll
et al., 2015) evaluated the suppression of ovarian function
after the supplementation of EE during HFI.
In 2004, Schlaff et al. randomly assigned 54 women to
receive one of these three different regimens: either 20 μg
EE + 100 μg LNG followed by seven pill-free days, or 20 μg EE
+ 150 μg DSG followed by 2 days of placebo then 10 μg EE for
5 days, or 28 days of 20 μg EE + 150 μg DSG. Ovarian inhibi-
tion was assessed by ultrasonographic evaluations and by mea-
surements of serum gonadotrophins, and daily urinary
conjugates of oestrogen and progesterone for two treat-
ment cycles. They demonstrated that women taking a con-
traceptive pill with a 7-day HFI showed an increased follicular
development compared with women who took a supplemen-
tation with either oestrogen alone or oestrogen plus proges-
tin (Schlaff et al., 2004).
Other authors led a prospective randomized study to es-
timate follicular growth and hormone concentrations with
three COC regimens before, during and after the 7-day HFI
or 7-day EE-supplemented interval. Thirty-three women were
enrolled and treated with a COC in the standard 21/7 regimen
for at least 2 months. Following that they were allocated to
treatment with 30 μg EE + 150 μg LNG according to one of
three different patterns: 150 μg LNG +30 μg EE for 21 days
followed by 7 days of placebo or 150 μg LNG + 30 μg EE for
84 days followed by 7 days of placebo or 150 μg LNG + 30 μg
EE for 84 days followed by 7 days of 10 μg EE. To evaluate
the degree of ovarian activity ultrasound scans were per-
formed and FSH, LH, oestradiol and inhibin B concentration
were measured. They showed that supplementation of the
standard 7-day HFI with 10 μg EE after 84 days of an ex-
tended COC reduced both FSH concentrations and the number
of growing follicles (Vandever et al., 2008).
In a randomized, open-label trial, Seidman et al. de-
scribed ovarian activity inhibition during a 21/7 day active
low-dose COC scheme that included only EE during the tra-
ditional HFI (150 μg DSG + 20 μg EE for 21 days + 7 days 10 μg
EE) and two 28-day regimens, a 24/4 day regimen of 3 mg
drospirenone (DRSP) + 20 μg EE 24 days + 4 days placebo and
a 21/7 regimen of 100 μg LNG + 20 μg EE for 21 days + 7 days
placebo. Ovarian activity suppression was examined by ul-
trasound scans and serum hormone measurements (proges-
terone, oestradiol, FSH and LH) and assessed using the H/S
score. All three regimens showed a low ovarian activity rate
(H/S grade 4 or 5), in particular 0% for 21 days DSG + EE + 7
days EE, 1% for 24 days DRSP + EE + 4 days placebo and 1%
for 21 days LNG + EE + 7 days placebo. A similar suppression
of serum hormone concentration was present in all three treat-
ments. The 21/7-active low-dose COC regimen (21 days DSG
+ EE + 7 days EE), that included only EE during the tradi-
tional HFI, showed the similar reduction of follicular devel-
opment that was observed during the 24 days DRSP + EE + 4
days placebo and the LNG + EE + 7 days placebo regimens
(Seidman et al., 2015).
Recently, Kroll et al. evaluated the role of a 91-day ex-
tended COC regimen (84 days of 150 μg LNG + 30 μg EE plus
7 days of 10 μg EE) on ovarian activity. Follicular develop-
ment was quantified using the H/S score. No luteinized,
unruptured follicles or ovulation were detected in the 35 sub-
jects included in the efficacy analysis during the first 28-day
interval; subsequently ovarian activity was detected in 1 of
35 women (2.9%) in the second 28-day interval; and in 2 of
35 women (5.7%) in the final 35-day interval. Overall, the
ovarian activity rate was 2.9% for the 91-day treatment period.
The authors concluded that the 91-day extended-regimen COC
with low-dose EE supplementation has shown to effectively
inhibit ovarian activity and suppress ovulation and women
showed good compliance (Kroll et al., 2015).
Progestogen-only pill (POP)
Natural progesterone or synthetic progestins contained in most
COC show a very low influence over FSH secretion. Follicu-
lar growth continues during administration of POP and, indeed,
in some low dose regimens, ovulation is not always inhib-
ited (Landgren and Diczfalusy, 1980). In fact, ovulation can
occur in 30–40% of POP users (McCann and Potter, 1994). Also
data obtained from progestin implants indicate a variable
degree of ovarian activity ranging from normal ovulatory cycles
to total suppression of follicle development (Mäkäräinen et al.,
1998). Only one randomized study evaluated the effect of a
POP on ovarian function (Duijkers et al., 2015). This random-
ized trial compared the effect on follicular development of
a POP containing 75 μg DSG and a new POP containing 4 mg
DRSP in a 24/4-day regimen. Follicular diameter, serum oes-
tradiol (oestradiol) and progesterone concentrations were
measured to determine H/S scores. Both treatments effec-
tively suppressed ovulation, which was demonstrated by the
similar follicular diameters, oestradiol concentrations and H/S
scores. The authors concluded that the new DRSP-only pill was
as effective as the DSG-only pill in inhibiting ovulation.
Subdermal contraceptive implants
Three prospective studies evaluated ovarian activity in women
using subdermal contraceptive implants (Alvarez-Sanchez
et al., 2000; Brache et al., 2000; Shaaban et al., 1993).
Shaaban et al. studied the probability of ovulation and sub-
clinical abortion in 50 women who were using a LNG implant
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(Norplant) for >1 year compared with 35 ovulatory cycles in
normal fertile women not using contraception. Sonographic
and hormonal evidence of ovulation were observed in one third
of LNG implant users; two of them resulted in conception.
However, the majority of these ovulatory cycles showed low
midcycle peaks of oestradiol, FSH and LH, and evidence of
luteal phase defect (LPD). LNG implant users had also sig-
nificantly thinner endometrium that did not exhibit the normal
phasic changes in sonographic texture. Furthermore, exces-
sive follicular enlargement was observed in 46% of the cycles
of LNG implant users (Shaaban et al., 1993).
Other authors evaluated the ovarian activity in women using
Nestorone progestin (NES). NES is a potent 19-norprogesterone,
which is active only via subdermal implants. This study com-
pared sonographic and endocrine parameters during use of
either one 4 cm or two 3 cm NES implants for 24 months. Sixty
participants were included in each dose group. Follicular de-
velopment was not fully suppressed during use of either NES
implant regimens, and serum oestradiol concentrations con-
tinuously <100 pmol/l were infrequently observed. Women
using the two-implant system showed stronger suppression of
ovarian activity, which was less than 5% during 18 months of
use, compared with those using the one-implant system, who
showed suppression of approximately 27%. On the other hand,
a single implant is easier to insert and remove (Brache et al.,
2000).
In 2000, Alvarez-Sanchez et al. enrolled 103 users of sub-
dermal LNG implants (Norplant) and 50 users of the TCu380A
intrauterine contraceptive device (IUD), to study with vaginal
ultrasonographic assay the presence of enlarged follicles. A
single blood sample for oestradiol and progesterone concen-
tration measurements was taken at the time of enrolment and
was repeated weekly in the women with enlarged follicles who
were being followed up until follicle involution. Follicles
greater than 25 mmwere revealed by ultrasonography in 17.5%
of LNG implant users and 4% of TCu380A IUD users, respec-
tively (P < 0.04). Progesterone concentrations were low in all
LNG implant users with enlarged follicles and were 17.4 and
8.7 nmol/l in the two users of the TCu380A IUD who had en-
larged follicles. At most, 4 weeks were necessary for the in-
volution of enlarged follicles (Alvarez-Sanchez et al., 2000).
Ovarian function following missed or delayed
doses of hormonal contraceptives
Hormonal contraception is very effective if correctly taken,
whilst incorrect use is the major cause of failure of the con-
traceptive. Five randomized studies and two prospective
studies evaluated the effect of a missing or delayed dose of
hormonal contraceptive on ovarian function (Brache et al.,
1999; Creinin et al., 2002; Elomaa et al., 1998; Mulders et al.,
2002; Petta et al., 1998, 2001; Pierson et al., 2003).
In a randomized study Creinin et al. evaluated follicular
development in 79 patients, using COC containing triphasic
NGM + EE (n = 40) or monophasic LNG + EE (n = 39), with in-
tentional imperfect compliance, for two months of treat-
ment. One group received a 35 μg EE preparation with NGM
180 μg (days 1–7), 215 μg (days 8–14) and 250 μg (days 15–
21). The second group received a 20 μg EE formulation with
LNG 100 μg (days 1–21). After completing a 28-day cycle,
women were instructed to extend the pill-free interval from
7 days to 9 days by missing on purpose the first two active
pills of the following blister pack. Women using LNG + EE de-
veloped follicles with a mean maximum diameter that was
significantly greater compared with women using NGM + EE
(P = 0.047). Median serum oestradiol concentrations were sig-
nificantly greater in women using LNG + EE compared with
those using NGM + EE on pill days 10 (P < 0.001) and 14 (P =
0.001). Progesterone concentration ≥3 ng/ml (considered con-
sistent with presumptive ovulation) was observed in two
women in the NGM + EE group and in three women in the LNG
+ EE group; nevertheless, follicles bigger than 13 mm were
not observed in these women. Women taking LNG + EE had
significantly greater follicular activity after a longer HFI com-
pared with those taking triphasic NGM + EE. The authors stated
that although follicular development was significantly in-
creased among LNG + EE users as compared with NGM + EE
users following an extended pill-free interval, further studies
are required to assess the clinical importance of this result
(Creinin et al., 2002).
Another study investigated whether missing the first three
tablets of the hormone treatment scheme results in ovula-
tion by extending further the pill-free period from 7–10 days.
Ninety-nine women were randomized to receive one of three
contraceptive regimens: monophasic GSD consisting of 75 μg
GSD + 30 μg EE; triphasic GSD, consisting of 6 days of 50 μg
GSD + 30 μg EE, 5 days of 70 μg GSD + 40 μg EE and 10 days
of 100 μg GSD + 30 μg EE; monophasic DSG consisting of 150 μg
DSG + 20 μg EE. Pituitary-ovarian function was assessed by
ultrasound scans and determination of hormone concentra-
tions (oestradiol, progesterone and FSH). No ovulations were
described. However, FSH and oestradiol concentrations were
higher during the first seven pill-free days. After 10 pill-free
days, follicles with diameters >18 mm were detected in 24%,
24% and 40% of the monophasic GSD, triphasic GSD and mono-
phasic DSG groups, respectively. Finally, with missing doses
from the first one to three pills of a medication cycle, pre-
ovulatory follicles were frequently found, but without ovu-
lation occurrence (Elomaa et al., 1998).
In a prospective randomized trial, 158 women were en-
rolled and administered 25 μg depot medroxyprogesterone
acetate (DMPA) + 5 μg oestradiol cypionate (oestradiol C) with
injection on day 5 or on day 7 of their menstrual cycle. Pro-
gesterone serum concentrations were measured and vaginal
ultrasound examinations were performed to evaluate ovarian
activity. In women who received DMPA + oestradiol C on day
5 only follicles <16 mm were detected. Among those women
who received DMPA + oestradiol C on day 7, 18% exhibited fol-
licles >16 mm and in 3% of this subgroup ovulation occurred.
Inhibition of ovarian activity was higher when the injection
of DMPA + oestradiol C was administered on day 5 rather than
on day 7 (Petta et al., 2001).
In 2002, Mulders et al. carried out an open-label random-
ized trial to evaluate ovarian activity in 45 women who used
an etonogestrel/ethinyl oestradiol vaginal ring (NuvaRing), who
were trained to follow, or not, the recommended scheme.
All women used the ring for one cycle according to the rec-
ommended regimen. Women in group A (n = 15) continued
with a ‘normal’ 3-week period of ring use. Following this their
ovarian function was monitored by daily vaginal ultrasound
and serum hormone concentrations. Women in group B (n =
15), continued with three consecutive days of ring use only,
after which each woman was observed until ovulation. Women
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in group C (n = 15) were not allowed to start a second ‘normal’
cycle until a follicle with a diameter of 13 mm was identi-
fied by ultrasound; subsequently, these participants started
another ‘normal’ cycle and follicular growth was monitored
daily. Despite the difference in second cycle length in group
A (3 weeks) and group B (3 days), a new cohort of follicles
developed in both groups and the time to ovulation after ring
removal was similar (19 versus 17 days). In group C the median
time to development of a follicle up to 13 mm in size was 11
days (range 8–21 days); none of the women in this group ovu-
lated after insertion of the second ring. The authors showed
that the etonogestrel/ethinyl oestradiol vaginal ring is a highly
effective, reversible method of hormonal contraception
(Mulders et al., 2002).
In a randomized open-label study the contraceptive patch
was compared with COC by maximum mean follicular diam-
eter and ovulation rate in normal cycles and after dosing
errors. The participants (n = 184) received either the 20-
cm2 patch designed to deliver 150 μg norelgestromin + 20 μg
EE daily to systemic circulation, (groups 1 and 2), or one of
three COC (a triphasic LNG COC containing 50 μg LNG + 30 μg
EE for days 1–6, 75 μg LNG + 40 μg EE for days 7–11, 125 μg
LNG 125 +30 μg EE 30 for days 12–21 and placebo for days 22–
28; a monophasic LNG COC containing 100 μg LNG + 20 μg EE
for days 1–21, a placebo for days 22–28; or a triphasic NGM
COC containing 180 μg NGM + 35 μg EE for days 1–7, 215 μg
NGM + 35 μg EE for days 8–14, 250 μg NGM + 35 μg EE for days
15–21 and placebo for days 22–28). Correct doses were used
in cycles 1, 2, 3 and 5 and dosing errors were planned for cycle
4, to give a shortened 10-day cycle. For cycle 4 in patch group
1 women wore one patch for the first 10 consecutive days.
In patch group 2 and the COC groups, the first seven dosing
days were followed by three drug-free days. After a 3-day
dosing error, follicular diameter was significantly smaller in
the patch group (mean, 7.0 mm) versus each COC group (range
of means, 11.8–17.1 mm). Similar results were seen after
correct dosing (group 1). Patch users demonstrated a signifi-
cantly lower incidence of ovulation compared with women
using COC. Follicular diameter and ovulation rate were sig-
nificantly reduced among patch users compared with COC users
in normal cycles and after dosing errors (Pierson et al., 2003).
Brache et al. designed a prospective study to determine
the timing of onset of contraceptive effectiveness in LNG
implant (Norplant) users when inserted in days 8–13 of the
cycle. Serum samples of oestradiol, progesterone, LH and
LNG were measured. Ovulation, as defined by progesterone
>2.5 ng/ml, occurred in 40% of participants. Therefore,
anovulatory cycles occurred in the remaining 60% of partici-
pants with two distinct oestradiol profiles: continuously
increasing oestradiol concentrations to a high mean of
0.41 ng/ml (28%), or no sustained increase in oestradiol
(32%). Since ovulation will either occur within 48 h of inser-
tion of the implant or will be impaired, additional
contraceptive protection is required for 3 days only (Brache
et al., 1999).
Petta et al. tried to determine by means of a prospective
study the timing of onset of contraceptive effectiveness after
the first injection of 150 μg of depot medroxyprogesterone
acetate (DMPA) administered in 30 women between days 8
and 13 of the menstrual cycle. Ovarian function was as-
sessed by serum concentrations of oestradiol and progester-
one and ultrasound scans monitoring follicular development.
All the ovulations occurred in nine (30%) of 30 women re-
ceiving DMPA between days 10 and 13 of the cycle. No woman
who received injections on day 8 or 9 ovulated. Women with
low ovarian activity showed a greater suppression of ovula-
tion. All the ovulations occurred within three days after the
injection. Therefore, an additional contraceptive method is
recommended until seven days after the first injection of DMPA
(Petta et al., 1998).
Follicle cysts and oral contraceptive use
It has been observed that women using POP showed an in-
creased tendency to develop functional ovarian cysts (Tayob
et al., 1985), probably related to the reduced impact of pro-
gestins on FSH secretion. In literature it is also documented
that there is a greater number of follicle cysts in women using
multiphasic and low-dose monophasic combined COC than in
those using moderate-dose monophasic COC (Lanes et al.,
1992). It is still not clear the mechanism underlying the growth
of follicle cysts during combined COC (Baerwald and Pierson,
2004). However, it is possible that low-dose COC do not protect
against functional cysts formation to the same extent as high-
dose formulations and it could be related to lower
hypothalamo-pituitary ovarian suppression.
Two randomized (Broome et al., 1995; Egarter et al., 1995),
one cohort (Lanes et al., 1992) and two case-control studies
(Holt et al., 1992, 2003) evaluated the risk of functional
ovarian cyst development during COC use.
Egarter et al. investigated in a randomized study the pres-
ence of ovarian follicles and cysts with ultrasound evalua-
tion and determined serum hormone concentrations in 65
women receiving either 20 μg EE + 150 μg DSG (group A) or
35 μg EE + 250 μg NGM (group B) for two treatment cycles.
Before starting hormonal therapy, at least one follicle <35 mm
in diameter was observed in 39% of women in group A and 31%
in group B. By the end of the 2-month study period, follicles
<35 mm were detected in only 14% of women in each group.
An ovarian cyst >35 mm was found in only one subject who
received the 35 μg EE preparation. Ovulation, identified by
hormone concentrations, was documented in one subject in
each group; no pregnancy occurred in either group. Women
receiving lower dose oestrogen COC did not show an in-
creased incidence of ovarian follicles or cysts compared with
women using a 35 μg EE preparation, and this could be ex-
plained by the type and dose of the progestin used (Egarter
et al., 1995).
Holt et al. evaluated in 106 women the risk of functional
ovarian cyst development, with surgical or ultrasound evalu-
ation, during the use of monophasic or triphasic COC. Com-
pared with women not using hormonal contraception, the
relative risks of a diagnosed functional ovarian cyst among
women currently using COC were 0.8 for users of monopha-
sic COC and 1.3 for users of triphasic COC. The results of this
study suggest that subjects currently using low-dose mono-
phasic COC do not have a substantially decreased risk of func-
tional ovarian cyst formation. According to this study the use
of triphasic COC does not increase the risk of functional ovarian
cysts (Holt et al., 1992).
In 2003, a case-control study was conducted to deter-
mine whether COC and tubal sterilization affects functional
ovarian cyst risk. They enrolled women, in particular 392 cases
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and 623 controls, showing at ultrasound scan or during surgery
a functional ovarian cyst. Women in the case group re-
ceived the following different types and doses of COC: greater
than 35 μg EE monophasic, 35 μg EE monophasic, less than
35 μg EE monophasic, multiphasic (triphasic and biphasic) and
POP. The purpose of the study was to evaluate the associa-
tion between the diagnosis of a functional ovarian cyst and
current contraceptive method. The overall odds ratio (OR) was
0.72 in women using COC, compared with women using non-
surgical, non-hormonal contraception or no contraception.
Women receiving 35 μg EEmonophasic COC had a slightly lower
risk (OR 0.69) of functional ovarian cyst compared with women
receiving less than 35 μg EE monophasic (OR 0.79) or multi-
phasic COC (OR 0.76). In conclusion, low-dose COC is asso-
ciated with a low or no influence on functional ovarian cyst
probability (Holt et al., 2003).
Other authors tried to determine whether multiphasic, low-
dose monophasic and high-dose monophasic COC have a similar
effect in inhibiting functional ovarian cysts development. They
enrolled 7462 healthy women and 32 women with evidence
of a functional ovarian cyst >20 mm in diameter. COC were
grouped into four types: multiphasic pills, low-dose mono-
phasic pills (≤35 μg oestrogen), high-dose monophasic pills
(>35 μg oestrogen) and POP. The incidence of functional
ovarian cysts was lower among women receiving multipha-
sic pills (rate ratio 0.91), low-dose monophasic pills with ≤35 μg
oestrogen (rate ratio 0.52) and high-dose monophasic pills with
>35 μg oestrogen (rate ratio 0.24), compared with women who
did not use a COC. Low-dose COC, with a smaller hormonal
potency, may show a slightly lower suppression of func-
tional ovarian cysts formation than high-dose monophasic pills
whose protective action is already known in literature (Lanes
et al., 1992).
Broome et al. in 1995 performed a randomized study of
17, 15 and 10 women who were administered triphasic con-
traceptives, progestins or nothing. The study aimed to es-
tablish whether the incidence of ovarian cyst development
was different among triphasic COC users or POP users, and
to evaluate the persistence of any diagnosed cysts. Women
were subcategorized into three groups by the contraceptive
method used. Group T comprised 17 subjects who had been
taking a triphasic COC for at least six treatment cycles. This
regimen consisted of 6 days of 30 μg EE + 50 μg LNG, 5 days
of 40 μg EE + 75 μg LNG and 10 days of 30 μg EE + 125 μg LNG,
followed by 7 tablet-free days. Group P included 15 women
who had been taking a POP either 30 μg LNG or 350 μg NET
daily for at least six months. Both groups T and P were studied
for three treatment cycles. Group C (the control group) in-
cluded 10 women who were not administered any hormonal
contraceptive or an IUD for at least 6 months. They were
studied like groups T and P over three months, during which
they did not take hormonal contraceptives. Ultrasound evalu-
ation was performed to count and measure follicles ranging
from 10 mm to 30 mm in size. Functional ovarian cysts con-
sisted of any fluid-filled formation greater than 30 mm in size
identified in the second half of the cycle that remained for
more than two cycles; an enlarged follicle was defined as any
analogous structure that did not persist. It was found that
women taking COC had a lower incidence of enlarged fol-
licles compared with women in the POP group. In addition,
the study showed that any swollen follicle was transitory
(Broome et al., 1995).
Conclusion
The purpose of this review is to give a complete evaluation
of residual ovarian activity during hormonal contraceptive use.
Unfortunately, it is difficult to draw a final conclusion because
the analysed studies are very heterogeneous. They evaluate
different outcome parameters such as AFC, AMH concentra-
tion, ovarian volume, VI, H/S scores, hormonal assay (FSH,
LH, oestradiol, progesterone, inhibin B, E1G, PdG and SHBG),
endometrial thickness and development of follicle struc-
tures; moreover, every type and dosage (EP or only proges-
tin) of hormonal contraceptive and every mode of
administration (oral, vaginal ring, implant or transdermal patch)
is used. Hence, it is very difficult to make a comparison of
the results. Nevertheless, important evidence emerges from
this analysis.
Follicular development continues during treatment with
hormonal contraceptives, although each regimen of ste-
roids inhibits ovulation, if taken correctly (Baerwald et al.,
2004; Crosignani et al., 1996; Spona et al., 1996; Young et al.,
1992).
During treatment with hormonal contraceptives FSH, LH
and oestradiol serum concentrations decrease (Deb et al.,
2012; Fitzgerald et al., 1994). There is also a reduction of the
endometrial thickness (Spona et al., 2010).
Some studies evaluate ovarian reserve parameters, namely
serum AMH concentration, AFC and ovarian volume among
users and non-users of hormonal contraception. In particu-
lar, Bentzen et al. show that AFC in all follicle size catego-
ries (small, 24 mm; intermediate, 5–7 mm; large, 8–10 mm)
is lower in users than in non-users of hormonal contracep-
tion, as well as AMH serum concentration (Bentzen et al.,
2012). Deb et al. instead, do not a find significant differ-
ence in serum AMH concentrations between these two groups
(Deb et al., 2012). As regards the effect of hormonal contra-
ception on AMH, there are still controversies in literature.
There are many articles about it, but none of them had been
included in our review because these studies did not fit the
inclusion criteria. Anyway, some authors claim that AMH con-
centration, both in healthy women and in those suffering from
polycystic ovary syndrome (PCOS), is not influenced by COC,
vaginal contraceptives, combined injectable contraceptive,
POP, progestogen-only injectable, LNG intrauterine system
or pregnancy (Li et al., 2011; Seifer and MacLaughlin, 2007;
Somunkiran et al., 2007; Streuli et al., 2008; Van den Berg
et al., 2010). Some other studies instead observe a reduc-
tion of AMH dosage during hormonal contraceptive use (Arbo
et al., 2007; Kallio et al., 2013; Kristensen et al., 2012; Panidis
et al., 2011).
During compliant COC use, follicular growth to a presum-
ably ovulatory size is observed, and that is associated with
loss of endocrine suppression that occurs during the HFI
(Baerwald et al., 2004).
The shorter HFI in COC with low-dose preparations may in-
crease the margin of safety in women. (Schlaff et al., 2004;
Spona et al., 1996; Sullivan et al., 1999). There is no agree-
ment whether the EE content (Van Heusden and Fauser, 1999)
or the progestin formulation (Rible et al., 2009) determines
the degree of residual ovarian activity at the beginning of HFI.
The lower-dose rather than the higher-dose monophasic pill
shows the same effectiveness of the multiphasic pill in its in-
hibition of follicular growth (Grimes et al., 1994).
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The continuous COC dosing regimens result more effec-
tive in preventing the ovulation and they are associated with
greater suppression of ovarian and endometrial function
(Archer et al., 2009; Birtch et al., 2006; Kroll et al., 2015;
Legro et al., 2008). Furthermore, a prospective randomized
study shows that supplementing the standard 7-day HFI with
EE 10 μg after 84 days of an extended COC, a reduction of
FSH concentrations and number of growing follicles (Vandever
et al., 2008).
The administration of EE in the HFI is controversial. Many
authors show that the administration of EE during HFI more
effectively suppresses the ovarian follicular activity (Killick
et al., 1998; Kroll et al., 2015; Schlaff et al., 2004), but a
recent randomized open-label trial documents that the 21/7
days of active low-dose COC preparation, with EE supple-
mentation during the traditional HFI, shows a similar inhibi-
tion of ovarian follicular activity compared with the 24/4 day
and the 21/7 day regimens (Seidman et al., 2015).
Low-dose COC use apparently does not increment the in-
cidence of functional ovarian cysts (Holt et al., 2003; Lanes
et al., 1992), and the occurrence of enlarged follicles is lower
among women with a COC compared with those using a POP
(Broome et al., 1995), although available studies are limited
so far. Similarly, few studies investigate the ovarian func-
tion following missed or delayed doses of hormonal contra-
ceptives. In most of these studies the follicular development
up to pre-ovulatory diameter is commonly described in women
delaying the first dose of their contraceptive cycle (Elomaa
et al., 1998; Mulders et al., 2002; Petta et al., 2001), but a
single study asserts that if the missed doses were restricted
to only three pills, normal ovulation was not observed (Elomaa
et al., 1998). Pierson shows that the ovulation rate was sig-
nificantly reduced for the patch users compared with COC
users. Contraceptive patch users showed follicular size and
incidence of ovulation significantly lower than women taking
COC in normal cycles and after predetermined dosing errors
(Pierson et al., 2003). Another study shows that the effec-
tiveness of oral contraception with imperfect compliance
differs according to the progestin formulation used, but to
establish the clinical relevance of this result, further studies
are required (Creinin et al., 2002).
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